Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study

Serotonin 1A (5-HT1A) binding potential (BP) as assessed by positron emission tomography (PET) is higher in major depressive disorder (MDD) in association with the higher expressing GG genotype of the 5-HT1A C-1019G polymorphism. We hypothesize that higher 5-HT1A BP and the GG genotype predict remission failure on antidepressant treatment. We determined 5-HT1A BP by PET and 5-HT1A C-1019G genotype in 43 controls and 22 medication-free MDD subjects. MDD was treated naturalistically and remission was defined as >50% reduction and a score of ⩽10 on the 24 item Hamilton Scale 1 year after initiation of treatment after scanning. Despite equivalent treatment, nonremitters have higher pretreatment cortical BP and the GG genotype is over-represented compared with remitters. Higher 5-HT1A BP, perhaps due to greater gene expression, may predict antidepressant medication nonremission. The findings should be tested in a controlled prospective treatment study.

[1]  M. Bauer,et al.  Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder. , 2003, Journal of psychiatric research.

[2]  Philippe Courtet,et al.  Serotonin transporter gene may be involved in short-term risk of subsequent suicide attempts , 2003, Biological Psychiatry.

[3]  Victoria Arango,et al.  Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635 , 2002, Brain Research.

[4]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[5]  P. Albert,et al.  Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. , 2004, The international journal of neuropsychopharmacology.

[6]  C. de Montigny,et al.  Modifications of the Serotonin System by Antidepressant Treatments: Implications for the Therapeutic Response in Major Depression , 1987, Journal of clinical psychopharmacology.

[7]  E. Baca-García,et al.  A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. , 2003, The Journal of clinical psychiatry.

[8]  A. Serretti,et al.  The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. , 2004, The international journal of neuropsychopharmacology.

[9]  H. Sackeim,et al.  The Impact of Medication Resistance and Continuation Pharmacotherapy on Relapse following Response to Electroconvulsive Therapy in Major Depression , 1990, Journal of clinical psychopharmacology.

[10]  G. R. Blakley,et al.  A Computer Algorithm for Calculating the Product AB Modulo M , 1983, IEEE Trans. Computers.

[11]  Gustavo Turecki,et al.  Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.

[12]  M. Bauer,et al.  Lithium Augmentation Increases the ACTH and Cortisol Response in the Combined DEX/CRH Test in Unipolar Major Depression , 2002, Neuropsychopharmacology.

[13]  F. Goodwin,et al.  Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression [proceedings]. , 1981, Psychopharmacology bulletin.

[14]  K. Suthers,et al.  Antidepressant response in late-life depression. , 1998, The Journal of clinical psychiatry.

[15]  D. Oslin,et al.  A functional prodynorphin promoter polymorphism and opioid dependence , 2005, Psychiatric genetics.

[16]  J. R. Painter,et al.  Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? , 2002, Journal of affective disorders.

[17]  R Ramana,et al.  Residual symptoms after partial remission: an important outcome in depression , 1995, Psychological Medicine.

[18]  Frederick K. Goodwin,et al.  Aggression in humans correlates with cerebrospinal fluid amine metabolites , 1979, Psychiatry Research.

[19]  W. Katon,et al.  Relapse of depression in primary care. Rate and clinical predictors. , 1998, Archives of family medicine.

[20]  Victoria Arango,et al.  Regional Heterogeneity of 5-HT1A Receptors in Human Cerebellum as Assessed by Positron Emission Tomography , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Ramin V. Parsey,et al.  Altered Serotonin 1A Binding in Major Depression: A [carbonyl-C-11]WAY100635 Positron Emission Tomography Study , 2006, Biological Psychiatry.

[22]  M. Keller,et al.  Remission versus response: the new gold standard of antidepressant care. , 2004, The Journal of clinical psychiatry.